Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ: MLTX ) 46.79 -0.69 (-1.45%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about MoonLake Immunotherapeutics - Class A Ordinary Shares MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis June 10, 2024 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa May 16, 2024 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions April 10, 2024 From Komodo Health Via Business Wire MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day March 10, 2024 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 March 04, 2024 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS) February 26, 2024 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis November 05, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa October 15, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress October 11, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 September 06, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update August 10, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts July 25, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire MarketBeat Week in Review – 6/26 - 6/30 July 01, 2023 Markets headed into a holiday week cheering a lower-than-expected key inflation reading, but investors should expect volatility in a short trading week. Via MarketBeat Topics Economy Exposures Interest Rates MoonLake Immunotherapeutics Makes a Moonshot on Trials June 28, 2023 Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results. Via MarketBeat Exposures Product Safety MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares June 28, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire BioMedNewsBreaks – MoonLake Immunotherapeutics’ (NASDAQ: MLTX) Shares See Significant Increase Based on Success of Phase 2 Trial June 26, 2023 Via Investor Brand Network MoonLake Immunotherapeutics (NASDAQ: MLTX) Announces Breakthrough Results for Sonelokimab in Phase 2 Trial June 26, 2023 MoonLake Immunotherapeutics (NASDAQ: MLTX) has made significant strides with the successful outcome of their Phase 2 MIRA trial for sonelokimab, Via Spotlight Growth MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa June 25, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today April 19, 2023 From MoonLake Immunotherapeutics AG Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.